RxDoctor Payments Data

Aftab Poshni, MD

Psychiatry · Crystal Lake, ILNPI 1821097924

Payments from drug & device makers

$14,979in general payments, 2019–2025

Across 848 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Corium, LLC$936
  • plus $6K from 24 others

What the payments were for

  • Food & beverage$14,86399%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,979 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$41,807
Medicare patients
135
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole25$37,531
VraylarCariprazine Hcl20$32,265
Invega SustennaPaliperidone Palmitate11$23,343
TrintellixVortioxetine Hydrobromide18$12,176
VyvanseLisdexamfetamine Dimesylate23$8,925
Olanzapine151$3,946
Clozapine80$3,920
Bupropion XlBupropion Hcl110$2,982
Aripiprazole84$2,861
Escitalopram Oxalate232$2,856
Clonazepam261$1,678
Gabapentin82$1,366
Divalproex Sodium ErDivalproex Sodium35$1,284
Trazodone Hcl130$1,203
Quetiapine Fumarate103$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,665$37,53125 claims
AbbVieVraylar$2,765$32,26520 claims
Johnson & JohnsonInvega Sustenna$575$23,34311 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$1,043$21,10141 claims
Almatica Pharma LLCSertraline Hcl$14$834110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Crystal Lake

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →